PH26569A - Veterinary treatment - Google Patents
Veterinary treatment Download PDFInfo
- Publication number
- PH26569A PH26569A PH37795A PH37795A PH26569A PH 26569 A PH26569 A PH 26569A PH 37795 A PH37795 A PH 37795A PH 37795 A PH37795 A PH 37795A PH 26569 A PH26569 A PH 26569A
- Authority
- PH
- Philippines
- Prior art keywords
- infection
- days
- ppm
- radical
- feed
- Prior art date
Links
- XZJAKURZQBNKKX-QFQDJZPHSA-N (3e)-3-[(2s)-1-hydroxy-2-[(1s,2s,6r)-2-[(e)-3-hydroxy-2-[(2r,3r,6s)-6-[(e,3s)-3-[(2r,3s,5r)-5-[(1s)-1-methoxyethyl]-3-methyloxolan-2-yl]but-1-enyl]-3-methyloxan-2-yl]prop-1-enyl]-6-methylcyclohexyl]propylidene]oxolane-2,4-dione Chemical compound O1[C@@H]([C@H](C)OC)C[C@H](C)[C@@H]1[C@@H](C)\C=C\[C@H]1O[C@@H](C(\CO)=C\[C@@H]2[C@H]([C@H](C)CCC2)[C@H](C)C(\O)=C\2C(OCC/2=O)=O)[C@H](C)CC1 XZJAKURZQBNKKX-QFQDJZPHSA-N 0.000 claims abstract description 42
- 208000015181 infectious disease Diseases 0.000 claims abstract description 42
- 241000589893 Brachyspira hyodysenteriae Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 241000282887 Suidae Species 0.000 abstract description 23
- 150000001875 compounds Chemical class 0.000 abstract description 19
- 241001465754 Metazoa Species 0.000 abstract description 14
- 241000282898 Sus scrofa Species 0.000 abstract description 13
- 208000001848 dysentery Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 241000192125 Firmicutes Species 0.000 abstract description 2
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 229950002881 tetronasin Drugs 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- -1 alkali metal salts Chemical class 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- 239000004189 Salinomycin Substances 0.000 description 13
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 13
- 229960001548 salinomycin Drugs 0.000 description 13
- 235000019378 salinomycin Nutrition 0.000 description 13
- 229930182504 Lasalocid Natural products 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 12
- 229960000320 lasalocid Drugs 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 229930191564 Monensin Natural products 0.000 description 6
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 6
- 229960005358 monensin Drugs 0.000 description 6
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000252983 Caecum Species 0.000 description 4
- 235000021052 average daily weight gain Nutrition 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229960000946 dimetridazole Drugs 0.000 description 3
- IBXPYPUJPLLOIN-UHFFFAOYSA-N dimetridazole Chemical compound CC1=NC=C(N(=O)=O)N1C IBXPYPUJPLLOIN-UHFFFAOYSA-N 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 3
- 229960004885 tiamulin Drugs 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000486634 Bena Species 0.000 description 1
- 208000034598 Caecitis Diseases 0.000 description 1
- 101100190462 Caenorhabditis elegans pid-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001134665 Streptomyces longisporoflavus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002460 polyether antibiotic agent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 229960000887 spectinomycin hydrochloride Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Cephalosporin Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Feed For Specific Animals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB878726384A GB8726384D0 (en) | 1987-11-11 | 1987-11-11 | Veterinary treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26569A true PH26569A (en) | 1992-08-19 |
Family
ID=10626769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH37795A PH26569A (en) | 1987-11-11 | 1988-11-10 | Veterinary treatment |
Country Status (11)
Country | Link |
---|---|
US (1) | US4999374A (de) |
EP (1) | EP0316163B1 (de) |
JP (1) | JP2706494B2 (de) |
AT (1) | ATE87478T1 (de) |
AU (1) | AU608093B2 (de) |
CA (1) | CA1318601C (de) |
DE (1) | DE3879877T2 (de) |
DK (1) | DK627188A (de) |
GB (1) | GB8726384D0 (de) |
IE (1) | IE63427B1 (de) |
PH (1) | PH26569A (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9806029D0 (en) * | 1998-03-20 | 1998-05-20 | Merck & Co Inc | 8a-Azalides as veterinary antimicrobial agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331658A (en) * | 1977-05-31 | 1982-05-25 | Eli Lilly And Company | Method of treating swine dysentery with antibiotic A-32887 |
GB2027013B (en) * | 1978-08-03 | 1983-03-30 | Ici Ltd | Compound m 139603 from streptomyces longisporoflavus and its use in ruminants |
DE3275091D1 (en) * | 1981-07-16 | 1987-02-19 | Ici Plc | Derivatives of m.139,603 useful as growth promotors |
US4537956A (en) * | 1983-11-23 | 1985-08-27 | Hoffmann-La Roche Inc. | Antibiotics X-14889 A, C and D |
ES8802229A1 (es) * | 1985-04-30 | 1988-04-16 | Glaxo Group Ltd | Un procedimiento para preparar nuevos derivados lactonicos macrociclicos. |
-
1987
- 1987-11-11 GB GB878726384A patent/GB8726384D0/en active Pending
-
1988
- 1988-11-10 AU AU25007/88A patent/AU608093B2/en not_active Ceased
- 1988-11-10 AT AT88310571T patent/ATE87478T1/de active
- 1988-11-10 DE DE8888310571T patent/DE3879877T2/de not_active Expired - Fee Related
- 1988-11-10 PH PH37795A patent/PH26569A/en unknown
- 1988-11-10 CA CA000582789A patent/CA1318601C/en not_active Expired - Fee Related
- 1988-11-10 EP EP88310571A patent/EP0316163B1/de not_active Expired - Lifetime
- 1988-11-10 JP JP63284814A patent/JP2706494B2/ja not_active Expired - Lifetime
- 1988-11-10 IE IE336988A patent/IE63427B1/en not_active IP Right Cessation
- 1988-11-10 DK DK627188A patent/DK627188A/da not_active Application Discontinuation
- 1988-11-14 US US07/270,002 patent/US4999374A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK627188D0 (da) | 1988-11-10 |
JPH01153631A (ja) | 1989-06-15 |
IE63427B1 (en) | 1995-04-19 |
AU2500788A (en) | 1989-05-25 |
DE3879877T2 (de) | 1993-07-08 |
DK627188A (da) | 1989-05-12 |
DE3879877D1 (de) | 1993-05-06 |
ATE87478T1 (de) | 1993-04-15 |
EP0316163A3 (en) | 1990-06-27 |
EP0316163A2 (de) | 1989-05-17 |
AU608093B2 (en) | 1991-03-21 |
GB8726384D0 (en) | 1987-12-16 |
CA1318601C (en) | 1993-06-01 |
JP2706494B2 (ja) | 1998-01-28 |
EP0316163B1 (de) | 1993-03-31 |
US4999374A (en) | 1991-03-12 |
IE883369L (en) | 1989-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1297410C (en) | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same | |
JPH0335796A (ja) | 環状デプシペプチド物質およびその製造法、ならびにそれを含有する駆虫剤 | |
NZ337080A (en) | Oral preparation containing xanthophylles such as astaxanthin to helicobacter sp.infection | |
CN102205126A (zh) | 儿茶素类物质联合后与抗菌药物的联合的应用 | |
CN110201035A (zh) | 一种禽用植物精油组合物及其制备方法和应用 | |
KASAI et al. | In vivo antibacterial activity of cefodizime, a new cephalosporin antibiotic | |
KR970007189B1 (ko) | 항콕시듐증 조성물, 이를 함유하는 동물 사료 및 동물 사료 첨가제 예비 혼합물 | |
EP0009686B1 (de) | Ein Phosphonsäurederivat enthaltende antibakterielle Mischung | |
PH26569A (en) | Veterinary treatment | |
CN115192593B (zh) | 柔红霉素在治疗多重耐药菌感染疾病中的应用 | |
US5721242A (en) | Antibiotic combination | |
EP0213692B1 (de) | Verwendung von Hygromycin und Epihygromycin zur Behandlung von Dysentrie bei Schweinen | |
EP0621783A1 (de) | Clavulansäuresalz und erythranycinderivate enthaltende pharmazeutische zusammensetzungen | |
JPH06217708A (ja) | 水生生物種のグラム陽性菌疾患の治療薬 | |
EP0369503B1 (de) | Methode zur Kontrolle von Pneumocystis carinii | |
US6328989B1 (en) | Use of bicozamycin for the manufacture of a medicament for treating infections with enterohemorrhagic e. coli | |
Hewitt | Use of antibiotics in the treatment of experimental diphtheria infections | |
Craven | Salmonella typhimurium, hydrophobic antibiotics, and the intestinal colonization of broiler chicks | |
JP5758602B2 (ja) | ホスホマイシンを有効成分とする魚類のエドワジエラ症治療剤 | |
Vebmeulen et al. | Experimental Urolithiasis VIII: Furadantin in Treatment of Experimental Proteus Infection with Stone Formation | |
CN112603916A (zh) | 月桂酸在制备沙门氏菌ⅲ型分泌系统抑制剂中的应用 | |
AU7570891A (en) | Veterinary treatment of lambs and sheep | |
KR930006040A (ko) | 항생물질 ll-e19020 감마, 및 이의 생산 방법 | |
JPS58107141A (ja) | 家畜の発育促進・飼料効率改善剤 | |
CN87100799A (zh) | 鱼用抗菌药物 |